Ersin İBİŞOĞLU, Hacı Murat GÜNEŞ, Filiz KIZILIRMAK, Beytullah ÇAKAL, Oguz KARACA, Mehmet Onur OMAYGENÇ, Ekrem GÜLER, Gültekin Günhan DEMİR, Fatih Erkam OLGUN, Ümeyir SAVUR, Deniz Dilan NAKİ, Bilal BOzTOSUN

Long-Term Outcomes of Patients Presenting with Acute Coronary Syndrome and Implanted with Bioresorbable Scaffold

A bioresorbable scaffold (BRS) has been used in the latest stages of stent technology and is a less-known material than drug-eluting stents (DES). In this study, we aimed to evaluate the long-term clinical outcomes of BRS in patients presenting with non-ST-segment elevation myocardial infarction (NSTEMI), a type of acute coronary syndrome (ACS). 39 patients and 53 lesions who applied to Istanbul Medipol University Faculty of Medicine Hospital between June 2015 and April 2016 with a diagnosis of NSTEMI and were treated with BRS were included in the study. The 4-year follow-up of the patients between 2016 and 2020 was recorded. Endpoints for the study were device success, treatment success, stent thrombosis, restenosis, and major adverse cardiac events (MACE). Operations were performed with a device success rate of 98.1% and a treatment success rate of 98.1%. No death or stent thrombosis was detected in any patient, and target lesion revascularization (TLR) occurred in one patient. The total rate of MACE was found to be 1.9%. Complications developed in two patients during the procedure and hospitalization and in four patients during the 4-year follow-up. If BRS are implanted by experienced surgeons in NSTEMI patients, it has been observed that the complication rate in the early period is low, and the complication rate increases depending on the type of stent chosen in the late period. To obtain better results, a BRS with good radial strength, thinner strut thickness, and rapid deployment should be achieved.

PDF

___

1. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. N Engl J Med 2015; 373: 1905-1915.
2. Moscarella E, Ielasi A, de Angelis MC, di Uccio FS, Cerrato E, de Rosa R, et al. Are acute coronary syndromes an ideal scenario for bioresorbable vascular scaffold implantation? Vol. 9, Journal of Thoracic Disease. AME Publishing Company 2017; 969-978.
3. Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrié D, Piek JJ, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet 2016; 388: 2479-2491.
4. Katsikis A, Serruys PW. Bioresorbable scaffolds versus metallic stents in routine PCI: The plot thickens. J Thorac Dis 2017; 9: 2296-300.
5. Wayangankar SA, Ellis SG. Bioresorbable Stents: Is This Where We Are Headed? Prog Cardiovasc Dis 2015; 58: 342-355.
6. Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, et al. A next-generation bioresorbable coronary scaffold system: From bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovasc Interv 2014; 7: 89-99.
7. Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, et al. Incidence, Mechanism, Predictors, and Long-Term Prognosis of Late Stent Malapposition after Bare-Metal Stent Implantation. Circulation 2004; 109: 881-886.
8. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK, et al. Late stent malapposition after drug-eluting stent implantation: An intravascular ultrasound analysis with long-term follow-up. Circulation 2006; 113: 414-419.
9. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution o. Eur Heart J 2014; 35: 2541-2619.
10. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: Change in paradigm of coronary revascularization in the upcoming decade? Vol. 33, European Heart Journal. Eur Heart J 2012; 16-25.
11. Arroyo D, Togni M, Puricel S, Gerard B, Sonja L, Corpataux N, et al. Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: Study protocol of the randomized controlled EVERBIO II trial. Trials 2014; 15(1).
12. Sabaté M, Windecker S, Iñiguez A, Okkels-Jensen L, Cequier A, Brugaletta S, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: Results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J 2016; 37: 229-240.
13. Dudek D, Rzeszutko L, Zasada W, Depukat R, Siudak Z, Ochala A, et al. Bioresorbable vascular scaffolds in patients with acute coronary syndromes: The POLAR ACS study. Pol Arch Med Wewn 2014; 124: 669-677.
14. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015; 10: 1144-1153.
15. Kraak RP, Hassell MECJ, Grundeken MJ, Koch KT, Henriques JPS, Piek JJ, et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry. EuroIntervention 2015; 10: 1160-1168.
16. Wöhrle J, Naber C, Schmitz T, Schwencke C, Frey N, Butter C, et al. Beyond the early stages: Insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention 2015; 11: 149-156.
17. Brown AJ, McCormick LM, Braganza DM, Bennett MR, Hoole SP, West NEJ. Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation. Catheter Cardiovasc Interv 2014; 84: 37-45.
18. Mattesini A, Secco GG, Dall’Ara G, Ghione M, Rama-Merchan JC, Lupi A, et al. ABSORB biodegradable stents versus second-generation metal stents: A comparison study of 100 complex lesions treated under OCT guidance. JACC Cardiovasc Interv 2014; 7: 741-750.
19. Otsuka F, Pacheco E, Perkins LEL, Lane JP, Wang Q, Kamberi M, et al. Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE v stent in a porcine coronary artery model. Circ Cardiovasc Interv 2014; 7: 330-342.
20. Kirtane AJ, Stone GW. How to minimize stent thrombosis. Circulation. 2011 Sep 13; 124: 1283-1287.
21. Tamburino C, Latib A, Van Geuns RJ, Sabate M, Mehilli J, Gori T, et al. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: A European perspective. Vol. 11, EuroIntervention. EuroPCR 2015; 45-52.
22. Piegza J, Desperak P, Kowalczyk J, Gierlotka M, Hawranek M, Chodór P, et al. Early and long-term outcomes of bioresorbable vascular scaffolds in the treatment of patients with coronary artery disease in real-world clinical practice - Insights from the ZABRZE-BVS registry. Postep w Kardiol Interwencyjnej. 2018; 14: 338-346.
23. Stone GW, Ellis SG, Gori T, Metzger DC, Stein B, Erickson M, et al. Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial. Lancet 2018; 392: 1530-1540.